Brown M J, Sharma P, Stevens P A
Clinical Pharmacology Unit, University of Cambridge, Centre for Clinical Investigation (ACCI), UK.
J Cardiovasc Pharmacol. 2000;35(4 Suppl 2):S41-43. doi: 10.1097/00005344-200000002-00010.
The genes for endothelin (ET) and their receptors are candidates for essential hypertension. Those for ET-1, ET-2 and the ET(A) receptor were selected for mutation scanning, and associated studies comparing untreated hypertensive patients and matched controls. A number of silent polymorphisms were found, resulting from a single nucleotide insertion or a single nucleotide substitution. There were no significant differences in the frequency of any one of these between the two groups. However, for ET-1 and ET-2 there were significant differences in the quantitative measurements of blood pressure and the number of variant alleles. The variants which we have found are likely to be in linkage disequilibrium with so far undiscovered variants in the regulatory regions of the genes.
内皮素(ET)基因及其受体是原发性高血压的候选基因。选择ET-1、ET-2基因和ET(A)受体进行突变扫描,并对未经治疗的高血压患者和匹配的对照组进行相关研究。发现了许多由单核苷酸插入或单核苷酸替换导致的沉默多态性。两组之间这些多态性的频率没有显著差异。然而,对于ET-1和ET-2,血压的定量测量和变异等位基因数量存在显著差异。我们发现的这些变异可能与基因调控区域中尚未发现的变异处于连锁不平衡状态。